Previous 10 | Next 10 |
– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings – – Former Chief Medical Officer for ...
– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director – – Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Co...
BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19,...
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ:...
Miller Value Partners is a value investor. It values businesses, and not just stocks, and invests in them for the long term. During the third quarter of 2020, Miller Opportunity Equity returned 13.01% (net of fees) versus the unmanaged benchmark, the S&P 500 Index, return of 8.93%...
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ziopharm Oncology Inc (ZIOP) Q3 2020 Earnings Call Transcript
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation
ZIOPHARM Oncology, Inc. (ZIOP) Q3 2020 Earnings Conference Call November 05, 2020 04:30 PM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Laurence Cooper - Chief Executive Officer Sath Shukla - Chief Financial Officer Adam Levy - Executi...
ZIOPHARM Oncology (ZIOP): Q3 GAAP EPS of -$0.10 misses by $0.01.Cash and cash equivalents of $135.5MPress Release For further details see: ZIOPHARM Oncology EPS misses by $0.01
– Company plans to file IND for Ziopharm TCR-T program in Q1 of next year for its Library “hotspot” trial – – Eden BioCell on track for IND filing i n Taiwan for autologus CAR-T clinical trial t...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...